Raymond James & Associates Sells 17,253 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Raymond James & Associates cut its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 45.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,467 shares of the medical instruments supplier’s stock after selling 17,253 shares during the period. Raymond James & Associates’ holdings in ICU Medical were worth $2,041,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ICUI. American Century Companies Inc. lifted its stake in ICU Medical by 6.4% in the first quarter. American Century Companies Inc. now owns 4,035 shares of the medical instruments supplier’s stock valued at $898,000 after buying an additional 243 shares during the period. Group One Trading L.P. lifted its stake in ICU Medical by 54.6% in the first quarter. Group One Trading L.P. now owns 566 shares of the medical instruments supplier’s stock valued at $126,000 after buying an additional 200 shares during the period. PNC Financial Services Group Inc. lifted its stake in ICU Medical by 110.5% in the first quarter. PNC Financial Services Group Inc. now owns 2,766 shares of the medical instruments supplier’s stock valued at $615,000 after buying an additional 1,452 shares during the period. Acadian Asset Management LLC lifted its stake in ICU Medical by 1,098.4% in the first quarter. Acadian Asset Management LLC now owns 3,020 shares of the medical instruments supplier’s stock valued at $672,000 after buying an additional 2,768 shares during the period. Finally, MetLife Investment Management LLC lifted its stake in ICU Medical by 33.3% in the first quarter. MetLife Investment Management LLC now owns 12,896 shares of the medical instruments supplier’s stock valued at $2,871,000 after buying an additional 3,221 shares during the period. 96.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, KeyCorp boosted their price target on ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $123.00.

Insider Transactions at ICU Medical

In other news, VP Daniel Woolson sold 791 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $98.27, for a total transaction of $77,731.57. Following the transaction, the vice president now directly owns 13,980 shares of the company’s stock, valued at $1,373,814.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Daniel Woolson sold 791 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $98.27, for a total transaction of $77,731.57. Following the transaction, the vice president now directly owns 13,980 shares of the company’s stock, valued at $1,373,814.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christian B. Voigtlander sold 13,603 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $107.19, for a total value of $1,458,105.57. The disclosure for this sale can be found here. Insiders have sold 24,262 shares of company stock valued at $2,545,532 over the last ninety days. 6.70% of the stock is owned by company insiders.

ICU Medical Price Performance

Shares of ICUI opened at $96.33 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.06 and a current ratio of 2.53. ICU Medical, Inc. has a 52-week low of $78.28 and a 52-week high of $212.43. The business’s 50 day moving average price is $102.48 and its two-hundred day moving average price is $98.81. The firm has a market cap of $2.35 billion, a PE ratio of -78.32 and a beta of 0.69.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.39. ICU Medical had a positive return on equity of 6.35% and a negative net margin of 1.31%. The company had revenue of $587.86 million for the quarter, compared to analyst estimates of $564.77 million. On average, equities analysts anticipate that ICU Medical, Inc. will post 3.52 EPS for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.